Pure ethanol in experimental animal studies, may not primarily be carcinogenic, but secondarily it can act chemically and synergistically as a co-carcinogen via its endogenous metabolites and associated dietary and exogenous factors. However, ethanol, being a small molecule and miscible with water and most lipids, can readily enter cell membranes and directly affect cell function. In an in vitro study where ethanol was added to the culture medium for Lewis lung carcinoma, a dose-dependent suppression of tumour growth occurred. In the in vivo study, sequestration of the Lewis lung carcinoma in the lungs followed tail-vein injection in C57BL/6 mice. Starting on the second day after tumour implantation, primary pulmonary exposure was carried out with inhalations of 0.4% ethanol vapour from an aerosol for 70 min daily, this was continued for 17 days. This resulted in a marked reduction of the pulmonary tumour growth. Exposure to 0.1% ethanol vapour did not significantly affect the growth of Lewis lung carcinoma tumour. The optimum ethanol aerosol applications may thus be tumoricidal. Whether any ethanol secondary metabolites are involved is as yet uncertain.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF01612675 | DOI Listing |
bioRxiv
January 2025
Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037, United States.
Adoptive T-cell transfer has revolutionized the treatment of hematological malignancies. However, this approach has had very limited success in treating solid tumors, largely due to inadequate infiltration of vascularly administered T cells at tumor sites. The shear-resistant interaction between endothelial E-selectin and its cognate ligand expressed on leukocytes, sialyl Lewis X (sLe), is an essential prerequisite for extravasation of circulating leukocytes.
View Article and Find Full Text PDFJ Heart Lung Transplant
January 2025
The International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry, Chicago, IL.
Pharmaceutics
January 2025
Department of Materials Science, Graduate School of Pure and Applied Sciences, University of Tsukuba, Tennoudai 1-1-1, Tsukuba 305-8573, Ibaraki, Japan.
Orally administered sorafenib has shown limited improvement in overall survival for non-small-cell lung cancer patients, likely due to poor pharmacokinetics and adverse effects, including gastrointestinal toxicity. To address these issues, we developed silica-containing antioxidant nanoparticles (siRNP) as a carrier to enhance the therapeutic efficacy of lipophilic sorafenib. Sorafenib was loaded into siRNP via dialysis (sora@siRNP).
View Article and Find Full Text PDFChron Respir Dis
January 2025
South Texas Veterans Health Care System, University of Texas Health, San Antonio, TX, USA.
Background: The efficacy and safety of ensifentrine, a novel PDE3/PDE4 inhibitor, were previously evaluated in the ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) trials. Here, we present a pooled post-hoc subgroup analysis of patients according to background chronic obstructive pulmonary disease (COPD) maintenance medication regimens.
Objective: This analysis aimed to explore the efficacy and safety of ensifentrine in patients receiving long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists with inhaled corticosteroids (LABA + ICS).
Comb Chem High Throughput Screen
January 2025
Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Objective: This study aimed to investigate the effect of angelicin on the NSCLC tumor growth.
Background: Accumulating evidence shows that cancer-associated fibroblasts (CAFs) play an important role in tumor progression and metastasis, making CAFs an increasingly attractive target for therapeutic intervention. Targeted therapies against CAFs have been considered to have the potential to significantly improve cancer treatment outcomes, overcome resistance, and improve immune evasion.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!